INDV

Indivior PLC

16.75 USD

Last updated Dec 9, 19:13 UTC

Yesterday HIGH

$15.15

Yesterday LOW

$14.87

52w HIGH

$26.5

52w LOW

$14.6

EPS

0.34

PE

49.26

Next Earnings

Feb 27, 2024

Overview News Government Trades

Indivior PLC stock is down -8.17% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 9 December’s closed higher than November.

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Stock Exchange

NYSE

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

www.indivior.com/en

Benzinga Newsdesk

Thu Nov 9, 2023

Indivior Expects FY23 Net Revenue Of $1.03B-$1.09B Vs. Consensus Of $1.05B; Adjusted Gross Margin Of Low Mid 80% Range; Adjusted Operating Income Of $212M

Updated (November 9, 2023) July 27, 2023 Net Revenue (NR)1 No
Benzinga Newsdesk

Thu Nov 9, 2023

Indivior Q3 Adj EPS $0.34 Beats $0.30 Estimate, Sales $271.00M Beat $265.00M Estimate

Indivior (NASDAQ:INDV) reported quarterly adjusted earnings of $0.34 per share which beat the analyst consensus estimate of $0.30 by 13.33 percent. This is a 17.24 percent increase over earnings of $0.29 per share from
Lekha Gupta

Mon Oct 23, 2023

What's Going On With Pharma Company Indivior's Shares Today?

Indivior PLC (NASDAQ: INDV) shares are trading higher by around 6% after the company inked a deal to
Nina Zdinjak

Fri Oct 13, 2023

Publicly-Traded Addiction Treatment Co. Signs Exclusive Licensing Agreement With Alar Pharmaceuticals

Addiction treatment company Indivior PLC (NASDAQ: INDV) obtained exclusive global rights to develop, produce and commercialize Alar Pharmaceuticals’ portfolio of long-acting injectable formulations that release a prodrug1 of buprenorphine at varying durations, including its lead long-acting
Lisa Levin

Mon Oct 2, 2023

Why Intelligent Bio Solutions Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares climbed 86.1% to $0.2248 after the company said it is considering strategic alternatives for its non-core operations.
Vuk Zdinjak

Mon Aug 21, 2023

Indivior Reaches Agreement With End Payor Class To Resolve Their Antitrust Multi-District Litigation Claims

Indivior Inc., a subsidiary of Indivior PLC (NASDAQ: INDV) has reached an agreement to resolve the claims brought by the end payor class of litigants in the In re Suboxone Antitrust Litigation multi-district litigation.
Benzinga Newsdesk

Mon Aug 21, 2023

Indivior To Pay $30M To The End Payor Claimants As Part Of The Agreement To Resolve Their Antitrust Multi-District Litigation Claims
Benzinga Insights

Thu Jul 27, 2023

Earnings Scheduled For July 27, 2023

Companies Reporting Before The Bell • SES AI (NYSE:SES) is projected to report quarterly earnings at $0.11 per share on revenue of $337.60 million.
Benzinga Newsdesk

Thu Jul 27, 2023

Indivior Q2 EPS $0.39 Up From $0.31 YoY, Sales $276.00M Up From $221.00M YoY

Indivior (NASDAQ:INDV) reported quarterly earnings of $0.39 per share. This is a 25.81 percent increase over earnings of $0.31 per share from the same period last year. The company reported $276.00 million in sales this
Benzinga Insights

Tue Jun 13, 2023

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 32 companies reached new 52-week lows.